Bispecific Antibodies in Multiple Myeloma

Bispecific antibodies in the treatment of multiple myeloma - Nature

Bispecific antibodies are dual antigen targeting constructs that engage the T cells to plasma cells through various target antigens.

Bispecific Antibodies in Multiple Myeloma: Opportunities to Enhance ...

Bispecific antibodies represent a new treatment option for patients with myeloma. These antibodies activate the patient's own T-cells to kill ...

Bispecific Therapies | International Myeloma Foundation

Bispecific antibodies (also known as bispecifics, or BsAbs) are an immunotherapy (immune cell therapy) showing promising clinical trial results.

Bispecific Antibodies in Refractory Multiple Myeloma: Basics and ...

Bispecific antibodies such as teclistamab have yielded encouraging outcomes for patients with advanced multiple myeloma.

Bispecific Antibodies in Multiple Myeloma: Present and Future - PMC

Despite many recent advances in therapy, there is still no plateau in overall survival curves in multiple myeloma. Bispecific antibodies are a novel ...

Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients ...

The drug teclistamab became the first bispecific antibody to be approved by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma.

Infections following bispecific antibodies in myeloma: a systematic ...

In multiple myeloma, bispecific antibodies targets include B-cell maturation antigen (BCMA), cell surface marker FcRH5, or G protein–coupled ...

Bispecific Antibody Use in Patients With Lymphoma and Multiple ...

Cytokine release syndrome (CRS), all grades, is observed in approximately 55%-80% of the patients with relapsed or refractory multiple myeloma ...

Bispecific Antibodies for Myeloma Treatment

One of the newest classes of drugs in multiple myeloma is a group of therapies known as bispecific antibodies. They are a form of ...

Bispecific antibodies targeting BCMA, GPRC5D, and FcRH5 for ...

The first bispecific antibody (bsAb) for the treatment of relapsed/refractory multiple myeloma (RRMM), teclistamab, has been approved in 2022.

Current use of bispecific antibodies to treat multiple myeloma

This article focuses on the current use of BsAb in MM, reviewing the pre-clinical and clinical studies that support data-driven clinical decisions.

Dr Chari on Currently Available Bispecific Antibodies in Multiple ...

The first 2 BCMA-targeted bispecific antibodies that were FDA approved for the treatment of patients with multiple myeloma were teclistamab-cqyv ...

Bispecific antibodies for multiple myeloma: past, present and future

This review summarizes recent advances in bispecific antibodies for the treatment of refractory myeloma. It outlines the history of their development.

Improving outcomes with anti-BCMA bispecific antibodies ... - Nature

Therapies targeting BCMA are transforming the care of multiple myeloma, with unprecedented depth and durability of responses in patients ...

Bispecific antibodies for the treatment of relapsed/refractory multiple ...

Teclistamab is a bispecific antibody that targets BCMA expressed on the surface of myeloma cells and CD3 on the surface of T cells. In the multicohort phase I/ ...

T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma

Abstract. T cell–redirecting bispecific antibodies (BsAb) induce significant responses in heavily pretreated multiple myeloma. BsAbs are currently administered ...

Mechanisms of resistance against T-cell engaging bispecific ...

T-cell immunotherapies (CAR-T-cell therapy and bispecific antibodies) are transforming treatment for patients with multiple myeloma. Sequential use of T-cell ...

Breaking Down Bispecific Antibodies: A Conversation with Dr. Holly ...

Bispecific T-cell antibodies and chimeric antigen receptor (CAR) T-cells are highly effective novel therapies in multiple myeloma. These immunotherapies enhance ...

Bispecific Antibodies in Multiple Myeloma | Dana-Farber ... - YouTube

Omar Nadeem, MD, explains bispecific antibodies as an exciting new immunotherapy treatment option for patients with relapsed or refractory ...

International Myeloma Working Group immunotherapy committee ...

Here, we provide expert consensus clinical practice guidelines for the use of bispecific antibodies for the treatment of myeloma. The ...